Spyre Therapeutics, Inc. (SYRE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 5M 10M 15M Q1 '17: 982K Q2 '17: 1.5M Q3 '17: 1.3M Q4 '17: 1.5M Q1 '18: 1.5M Q2 '18: 2.4M Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '21: 0 Q2 '21: 13.7M Q3 '21: 1.4M Q4 '21: 3.6M Q1 '22: 1.4M Q2 '22: 625K Q3 '22: 174K Q4 '22: 168K Q1 '23: 198K Q2 '23: 688K Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q4 '17 Q4 '18 Q4 '19 Q4 '21 Q4 '22 Q4 '23 Q4 '24

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-180M -120M -60M 0 60M 120M 180M Q3 '16: -6.3M Q4 '16: -5.5M Q1 '17: -6.3M Q2 '17: -6.7M Q3 '17: -8M Q4 '17: -6.6M Q1 '18: -8.2M Q2 '18: -9.7M Q3 '18: -12.2M Q4 '18: -15.3M Q1 '19: -17.7M Q2 '19: -18.6M Q3 '19: -22.1M Q4 '19: -21.9M Q1 '20: -19M Q2 '20: -21.6M Q3 '20: -18.1M Q4 '20: -22.8M Q1 '21: -18.2M Q2 '21: -6.7M Q3 '21: -20.3M Q4 '21: -20.4M Q1 '22: -24.4M Q2 '22: -22.4M Q3 '22: -18.8M Q4 '22: -19.2M Q1 '23: -18.8M Q2 '23: -159.2M Q3 '23: -18.3M Q4 '23: -45.9M Q1 '24: -47.8M Q2 '24: -44.1M Q3 '24: -55.4M Q4 '24: -61.3M Q1 '25: -53.6M Q2 '25: -41.9M Q3 '25: -56.9M Q4 '25: -57.2M Q1 '26: -45.6M Q2 '26: -41.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-240M -160M -80M 0 80M 160M 240M Q3 '16: -6.2M Q4 '16: -5.5M Q1 '17: -6.2M Q2 '17: -6.6M Q3 '17: -7.9M Q4 '17: -6.5M Q1 '18: -8.1M Q2 '18: -9.4M Q3 '18: -11.9M Q4 '18: -14.9M Q1 '19: -17.2M Q2 '19: -18M Q3 '19: -21.6M Q4 '19: -21.5M Q1 '20: -18.7M Q2 '20: -21.4M Q3 '20: -18M Q4 '20: -22.7M Q1 '21: -18.2M Q2 '21: -6.8M Q3 '21: -20.3M Q4 '21: -20.4M Q1 '22: -24.4M Q2 '22: -22.3M Q3 '22: -18.2M Q4 '22: -18.8M Q1 '23: -18.4M Q2 '23: -217.1M Q3 '23: -40.1M Q4 '23: -63.2M Q1 '24: -43.9M Q2 '24: -38.8M Q3 '24: -69M Q4 '24: -56.3M Q1 '25: -44.8M Q2 '25: -36.7M Q3 '25: -11.2M Q4 '25: -62.5M Q1 '26: -69M Q2 '26: -36.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '16: -5.9M Q4 '16: -4.4M Q1 '17: -5.4M Q2 '17: -5.9M Q3 '17: -7.4M Q4 '17: -5.9M Q1 '18: -7.4M Q2 '18: -9M Q3 '18: -8.5M Q4 '18: -7.2M Q1 '19: -15.8M Q2 '19: -16.4M Q3 '19: -17.2M Q4 '19: -16.3M Q1 '20: -21.7M Q2 '20: -19.4M Q3 '20: -17.5M Q4 '20: -17.1M Q1 '21: -19.5M Q2 '21: 2.1M Q3 '21: -17M Q4 '21: -19.3M Q1 '22: -26.3M Q2 '22: -20.7M Q3 '22: -15.1M Q4 '22: -18.1M Q1 '23: -17.6M Q2 '23: -16.6M Q3 '23: -34.6M Q4 '23: -31M Q1 '24: -28.5M Q2 '24: -62.2M Q3 '24: -29.4M Q4 '24: -37.2M Q1 '25: -41M Q2 '25: -46.6M Q3 '25: -37.1M Q4 '25: -44.6M Q1 '26: -57.4M Q2 '26: -69.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '15: -2.5M Q2 '15: -3.9M Q3 '15: -3.9M Q4 '15: -873K Q1 '16: -4M Q2 '16: -4.7M Q3 '16: -5.9M Q4 '16: -4.5M Q1 '17: -5.7M Q2 '17: -6M Q3 '17: -7.5M Q4 '17: -6.1M Q1 '18: -7.5M Q2 '18: -9.1M Q3 '18: -8.6M Q4 '18: -7.4M Q1 '19: -15.9M Q2 '19: -16.4M Q3 '19: -17.4M Q4 '19: -17.5M Q1 '20: -23.1M Q2 '20: -20.7M Q3 '20: -18.1M Q4 '20: -18.1M Q1 '21: -20M Q2 '21: 2.1M Q3 '21: -17.1M Q4 '21: -19.3M Q1 '22: -26.3M Q2 '22: -20.7M Q3 '22: -15.1M Q4 '22: -18.1M Q4 '23: -31M Q3 '15 Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '21: 65.6M Q3 '21: 65.8M Q1 '22: 66M Q2 '22: 82.2M Q3 '22: 3.8M Q1 '23: 3.8M Q2 '23: 3.8M Q3 '23: 4.3M Q1 '24: 36.5M Q2 '24: 45.3M Q3 '24: 50.9M Q2 '21 Q1 '22 Q3 '22 Q2 '23 Q1 '24 Q3 '24

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-30.00 -15.00 0.00 15.00 30.00 45.00 Q4 '15: -19.08 Q1 '16: -21.47 Q2 '16: -19.49 Q3 '16: -14.39 Q4 '16: -8.44 Q1 '17: -1.81 Q2 '17: -1.82 Q3 '17: -1.83 Q4 '17: -1.81 Q1 '18: -1.83 Q2 '18: -1.82 Q3 '18: -1.88 Q4 '18: -2.11 Q1 '19: -2.21 Q2 '19: -2.30 Q3 '19: -2.42 Q4 '19: -2.45 Q1 '20: -2.43 Q2 '20: -2.28 Q3 '20: -1.91 Q4 '20: -1.61 Q1 '21: -1.32 Q2 '21: -1.02 Q3 '21: -1.04 Q4 '21: -25.02 Q1 '22: -25.11 Q2 '22: -25.28 Q3 '22: -29.81 Q4 '22: -10.17 Q1 '23: -14.69 Q2 '23: 25.72 Q2 '16 Q2 '17 Q2 '18 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.